Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Personal reasons
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to show that patch augmentation in rotatorcuff tear results in lower rate of recurrent tendon defects compared without patches.
An arthroscopic rotator cuff repair is nowadays mostly implemented in order to restore function and reduce or eliminate pain. The primary objective of this randomized controlled trial is to demonstrate, in patients 60 years or older with a large rotator cuff tear, that biological or synthetic patch augmen-tation in arthroscopic rotator cuff repair results in decreased rate of retear 24 months post-operatively compared to re-pair without patch augmentation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group 1: Pitch-Patch | Active Comparator | Reconstruction with patch augmentation using a synthetic patch |
|
| Intervention group 2: ArthroFlex | Active Comparator | Reconstruction with patch augmentation using a biological human dermis patch |
|
| Control | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pitch Patch | Device | The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ [PP]) augmentation. |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of retear | Repair integrity will be assessed by an independent assessor on the basis of centralized MRI images. | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Pain level (NRS) | The pain level in the operated shoulder will be measured with a numeric rating scale (0=no pain, 10 = maximum pain) as part as the Constant Murley Score (CS) | 6/24 months |
| Range of motion (flexion, abduction, external and internal rotation) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Osteoarthritis (grade ≥ 2 after Samilson & Prieto)
Advanced fatty infiltration of the rotator cuff muscles (Goutallier grade III or IV)
Tear of the subscapularis > Typ 1 Lafosse (partial tears of superior 1/3 of the tendon)
Irreparable tear of the supraspinatus
General medical contraindication to surgery
Known hypersensitivity to the materials used
Revision operations
Open reconstruction
Tendon transfer necessary (latissimus dorsi or pectoralis major)
Any disease process that would preclude accurate evaluation including:
Recent history of substance abuse
Legal incompetence
German language barrier to complete the questionnaires or
Participation in any other medical device or medicinal product study that could influence the results of the present study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Markus Scheibel, Prof | Schulthess Klinik | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000070636 | Rotator Cuff Injuries |
| ID | Term |
|---|---|
| D012421 | Rupture |
| D014947 | Wounds and Injuries |
| D000070599 | Shoulder Injuries |
| D013708 | Tendon Injuries |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ArthroFlex | Device | The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® [AF]) augmentation. |
|
The following active and passive range of motion parameters of the affected shoulder will be documented using a goniometer : Elevation (flexion), abduction, External rotation by 0° abduction, external-internal rotation by 90° abduction |
| 6/24 months |
| Shoulder strength in 90° abduction and in external rotation (0° abduction) | The shoulder strenght will be measured with an isobex device | 6/24 months |
| Constant Murley Score (CS) | The CMS is a 100-point scoring system that is divided into four subscales: pain (15 points), activities of daily living (20 points), range of motion (40 points) and strength (25 points).Pain and activities of daily living are self-reported by the patient using visual analog scales and ordinal categories. Range of motion is obtained during active painfree elevation in flexion and abduction (using a goniometer), and functional internal and external rotation of the shoulder (using ordinal scale). Strength testing was performed at 90° of abduction in the scapular plane. | 6/24 months |
| Oxford Shoulder Score (OSS) | The Oxford Shoulder Score used after 3 months is the primary parameter. The Score tests the ability to participate in the patients' normal life before they got injured. | 6/24 months |
| Subjective shoulder value (SSV) | The Subjective Shoulder Value (SSV) is based on a single question that is answered subjectively by the patients. The English formulation of this question is: "What is the overall percent value of your shoulder if a completely normal shoulder represents 100%?" | 6/24 months |
| Quality of life (utilities) and general health using EQ-5D-5L | EQ-5D is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal.Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status that can be used in the clinical and economic evaluation of health care as well as in population health surveys. | 6/24 months |
| Subjective improvement, expectation, satisfaction with treatment | Patients will be asked to assess their current state of health related to the operated shoulder at follow-up compared to the state before surgery. Further on A similar question will be asked regarding their perceived change in quality of life.At the 24-month follow-up questionnaire, patients will rate whether the surgical results met their expectations: | 6/24 months |
| Adverse events / complications | Adverse events will be analyzed according to their type and time of occurrence, severity and relation-to-implant: Local AEs within 24 months and Non-local AEs within 3 months | 3/6/24 months and intra-operative |